Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

The tumour suppressor function of the scaffolding protein spinophilin

 

Denis Sarrouilhe 1*, Véronique Ladeveze 2

1 Laboratoire de Physiologie Humaine, Faculté de Médecine et Pharmacie, Université de Poitiers, 6 rue de la Milétrie, Bât D1, TSA 51115, 86073 Poitiers, Cedex 9, France.
E-mail address: Denis.Sarrouilhe@univ-poitiers.fr
2 Laboratoire de Génétique Moléculaire de Maladies Rares, Université de Poitiers, UFR SFA, Pôle Biologie Santé, Bât B36, TSA 51106, 86073 Poitiers, Cedex 9, France.
E-mail address: Veronique.Ladeveze@univ-poitiers.fr

*Auteur correspondant: Tel/Fax: +33 5 49 45 43 58; E-mail address: Denis.Sarrouilhe@univ-poitiers.fr

 

February 2014

 

Key words: CaSR, G protein-coupled receptor, signaling

Abstract

Spinophilin is a scaffolding protein with modular domains that govern its interaction with a large number of cellular proteins. The Spinophilin gene locus is localized at chromosome 17q21, a chromosomal region frequently affected by genomic instability in different human tumours. The scaffolding protein interacts with the tumour-suppressor ARF which has suggested a role for Spinophilin in cell growth. More recently, in vitro and in vivo studies demonstrated that Spinophilin is a new tumour suppressor acting via the regulation of pRb. A clear downregulation of Spinophilin is found in several human cancer types. Moreover, Spinophilin loss is associated with a poor patient prognosis in carcinoma. Currently, there are controversial findings regarding a functional relationship between Spinophilin and p53 in cell cycle regulation and in carcinogenesis. Here we present the available data regarding Spinophilin function as a tumour suppressor.

1- Introduction

Protein phosphatase 1 (PP1) is a widespread expressed phosphoSerine/phosphoThreonine PP involved in many cellular processes (Ceulemans and Bollen, 2004). There are four isoforms of PP1 catalytic subunit (PP1c): PP1α, PP1β, PP1γ1 and PP1γ2, the latter two arising through alternative splicing (Sasaki et al., 1990). PP1c can form complexes with up to 50 regulatory subunits converting the enzyme into many different forms, which have distinct substrates specificities, restricted subcellular locations and diverse regulations (Cohen, 2002). In late 1990s, a novel PP1c binding protein that is a potent modulator of PP1 activity was characterized in rat brain and named spinophilin (Spn) (Allen et al., 1997). In the same time, two novel actin filament-binding proteins were purified from rat brain and named neurabin 1 and neurabin 2 (NEURal tissue-specific-Actin-Binding proteIN), and the latter was further identified as Spn (Nakanishi et al., 1997). Spn is expressed ubiquitously while neurabin 1 is expressed almost exclusively in neuronal cells. Spn exhibits the characteristics of scaffolding proteins with multiple protein interaction domains (Allen et al., 1997; Sarrouilhe et al., 2006). Scaffolding proteins link signalling enzymes, substrates and potential effectors (such as channels, receptors) into a multiprotein signalling complex that may be anchored to the cytoskeleton. In the years after this discovery, the spectrum of Spn partners and functions has expanded but has remained mostly in the field of neurobiology (Sarrouilhe et al., 2006). Spn has been implicated in the pathophysiology of several central nervous system (CNS) diseases, among which are Parkinson's disease, schizophrenia and mood disorders (Law et al., 2004; Brown et al., 2005). Spn is highly enriched at the synaptic membrane in dendritic spines, the site of excitatory neurotransmission and thus may control PP1 functions during synaptic activity (Ouimet et al., 2004). Spn regulates plasticity at the postsynaptic density (PSD) by targeting PP1c to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and N-methyl-D-aspartic acid (NMDA) receptors, promoting their down regulation by dephosphorylation and thus regulating the efficiency of post-synaptic glutamatergic neurotransmission. Spn and neurabin1 play different roles in hippocampal and striatal synaptic plasticity. Spn is involved in long-term depression (LTD) but not in long-term potentiation (LTP) whereas neurabin 1 contributes selectively to LTP but not LTD (Feng et al., 2000; Allen et al., 2006; Wu et al., 2008). In the same way, the two scaffolding proteins form a functional pair of opposing regulators that reciprocally regulate signalling intensity by some seven-transmembrane domain receptors (Wang et al., 2007). Thus, an emerging notion is that Spn and neurabin 1 may differentially affect their target proteins and perform quite distinctive function in cell.

Morphological studies have established that Spn is enriched at plasma membrane of cells although the protein is also expressed widely throughout the cytoplasm (Smith et al., 1999; Richman et al., 2001; Tsukada et al., 2003). Spn, which is expressed partly in the nucleus in mammalian cells, interacts in vitro and in vivo with the tumor-suppressor ARF (Alternative Reading Frame). Moreover, a role for Spn in cell growth was suggested, and this effect was enhanced by the interaction between Spn and ARF (Vivo et al., 2001). More recent studies showed that Spn is a new tumour suppressor and that a clear downregulation of this protein is found in several cancer types (Carnero, 2012). Furthermore, Spn loss is associated with poor patient prognosis in carcinomas (Sarrouilhe, 2014).

This review aims to outline the state of knowledge regarding Spn function in carcinogenesis.

2- Spinophilin structure

The primate (homo sapiens and Callithrix jacchus) Spn proteins contain 815 amino acids whereas the rodent Spn (rattus norvegicus and mus musculus) have 817amino acids. These sequences are very similar, with few amino acids substitutions compared to the human sequence in C-terminus but the N-terminus is more variable even if the variability is weak (Figure 1). Consequently, few differences are observed when we compared these sequences to the human one: the rat and human Spn proteins share 96% sequence identity (Allen et al., 1997; Vivo et al., 2001). In Cricetulus griseus, the sequence is shorter than the others: 631amino acids.

Figure 1. Alignment of amino acid sequences of spinophilin in different species. Blast and Align programs via UniProt site were used.

Gene analysis and biochemical approaches have contributed to define in Spn a number of distinct modular domains. This 130 kDa protein contains one F-actin-, a receptor- and a PP1c- binding domains, a PSD95/DLG/zo-1 (PDZ) and three coiled-coil domains. Figure 2 provides a schematic diagram of the main Spn structural domains.

Figure 2. Schematic drawing of spinophilin structure. The canonical protein phosphatase 1-binding domain is located within amino acids 447 and 451 in spinophilin.

In the five species of the Figure 1, the coiled-coil region has high identity with only one variation detected in Cricetulus griseus. The PDZ domain, the pentapeptide motif of PP1c -binding domain and the sextapeptide allowing the binding selectivity of PP1c isoforms, present the same identity. Moreover, the phosphoSer are conserved except the Ser-177 which is only detected in rat. Being not detected in mouse (G as in primates), Ser-177 is not a consequence of the rodent-specific high substitution rate.

Spn has been isolated from rat brain as a protein interacting with F-actin (Satoh et al., 1998). Its F-actin-binding domain determined to be amino acids 1-154 is both necessary and sufficient to mediate actin polymers binding and cross-linking. Nuclear Magnetic Resonance (NMR) and circular dichroism (CD) spectroscopy studies showed that Spn F-actin-binding domain is intrinsically unstructured and that upon binding to F-actin it adopts a more ordered structure (a phenomenom also called folding-upon-binding). Another actin binding property, namely a F-actin pointed end capping activity was recently proposed for this domain (Schüler and Peti, 2007). Spn, PP1c and F-actin can form a trimeric complex in vitro.

A receptor-interacting domain, located between amino acids 151-444, interacts with the third intracellular loop (3i) of various seven transmembrane domain receptors (Smith et al., 1999; Richman et al., 2001) such as the dopamine D2 receptor (D2R), some subtypes of the α-adrenergic (AR) and muscarinic-acetylcholine (m-AchR) receptors.

The primary PP1c-binding domain is located within residues 417-494 of Spn and this domain contains a pentapeptide motif (R-K-I-H-F) between amino acids 447 and 451 that is conserved in other PP1c regulatory subunits. A domain C-terminal to this canonical PP1-binding motif, located within amino acids 464 and 470, is essential for PP1 isoform selectivity in vitro and for selective targeting in cells (Carmody et al., 2008). Recently, the 3-dimentional structure of the PP1/Spn holoenzyme was determined. Spn is an unstructured protein in its unbound state that undergoes a folding transition upon interaction with PP1c into a single, stable conformation. The scaffolding protein binds to PP1c and blocks some potential substrate binding sites without altering its active site, then didacting substrate specificity of the enzyme (Ragusa et al., 2010). A further study showed that the PP1/Spn holoenzyme is dynamic in solution. The complex adopts a significant more extended conformation in solution than in the crystal structure. This is the result of a flexible linker (ramino acids 490-494) between the PP1c-binding and the PDZ domains. The four residue flexibility is likely important for Spn biological role (Ragusa et al., 2011).

Spn also contains a single consensus sequence in PDZ, amino acids 494-585 (Allen et al., 1997). The structure of the Spn PDZ domain has been recently solved by NMR spectroscopy. The PDZ domain directly binds to carboxy-terminal peptides derived from glutamatergic AMPA and NMDA receptors (Kelker et al., 2007).

Sequence analysis predicted that the carboxy-terminal region of Spn (amino acids 664-814) forms 3 coiled-coil domains. Neurabins were observed as multimeric forms in vitro and in vivo. Spn and neurabin 1 homo- and hetero-dimerize via their carboxy-terminal coiled-coil domains (MacMillan et al., 1999; Oliver et al., 2002).

Consensus sequences for phosphorylation by several protein kinases (PK), including cAMP-dependent PK (PKA), Ca2+/calmodulin-dependent PK II (CaMKII), cyclin-dependent PK5 (Cdk5), extracellular-signal regulated PK (ERK) and protein tyrosine kinases were observed in Spn. Two major sites of phosphorylation for PKA (Ser-177 not conserved in human, and Ser-94) and two others sites for CaMKII phosphorylation (Ser-100 and Ser-116) were located within and near the F-actin-binding domain of Spn. The protein is phosphorylated in intact cells by PKA at Ser-94 and Ser-177 and by CaMKII at Ser-100 (Hsieh-Wilson et al., 2003; Grossman et al., 2004). Moreover, neurabins can be phosphorylated in vitro and in intact cells by Cdk5 on Ser-17 and ERK2 (MAPK1) on Ser-15 and Ser-205, phosphoSer-17 being abundant in neuronal cells (Futter et al., 2005). Several potential tyrosine phosphorylation sites lie within the coiled-coil regions, within a region adjacent to the PDZ domain and within the receptor-interacting domain.

3- The Spinophilin interactome

Spn interactome includes cytoskeletal molecules (F-actin, doublecortin, neurabin 1, Spn), enzymes (like PP1 and CaMKII), regulator of G-protein signalling protein (like RGS8), guanine nucleotide exchange factors (like kalirin 7), membrane receptors [like the α-ARs, m-AChRs, D2R, δ- and μ-opioid receptors (OR) and cholecystokinin (CCK) receptors], and other proteins like ions channels [The transient receptor potential canonical (TRPC), the type 2 ryanodine receptor (RYR2)], TGN38 and ARF.

Shortly after the cloning of Spn as a novel PP1c-binding protein, another laboratory cloned this protein based on its ability to bind to F-actin (Satoh et al., 1998). Recombinant Spn and neurabin 1 interacted with each other when co-expressed in cells. On the other hand, recombinant Spn was shown to form homodimers, trimers or tetramers by interaction between coiled-coil domains. Spn homomeric complexes are thought to contribute to its actin-cross-linking activity (Satoh et al., 1998). Doublecortin (DCX) is a microtubule-associated protein that can induce microtubule polymerization and stabilize microtubules filaments. Immunoprecipitation experiments with brain extracts showed that Spn and DCX interact incultured cells (Tsukada et al., 2003). In vitro assays showed that DCX also binds to and bundles F-actin, suggesting that the protein cross-links microtubules and F-actin. The distribution of DCX between the two cytoskeletons can be regulated by Spn and by phosphorylation of DCX and it was proposed that Spn could localize and enhance the binding of phosphorylated DCX to F-actin (Tsukada et al., 2005).

Several studies have shown that Spn preferentially binds to PP1γ1 and PP1α isoforms in brain extracts (MacMillan et al., 1999; Terry-Lorenzo et al., 2002; Carmody et al., 2004). GST-Spn fusion proteins containing the PP1c-binding domain potently inhibit PP1 enzymatic activity in vitro (Allen et al., 1997; Colbran et al., 2003). However, it was recently shown that instead of inhibiting PP1c directly, Spn regulated enzymatic activity by directing its substrate specificity (Ragusa et al., 2010). Spn can associate with the tyrosine phosphatase SHP-1 and the complex modulates platelet activation by sequestering RGS10 and RGS18. The sequence surrounding the phosphorylation site Y398 in Spn fits a consensus ITIM sequence (I/V/L/SxY(p)xx(I/V/L) and forms a binding site for SHP1 (Ma et al., 2012). p70S6K is a mitogen-activated PK that regulates cell survival and growth. p70S6K interaction with neurabin 1 (Burnett et al., 1998) and Spn was demonstrated (Allen and Greengard, unpublished observation). The interaction implicates the PDZ domain of neurabins and the carboxyl-terminal five amino acids of the PK. CaMKII directly and indirectly associates with N- and C-terminal domains of Spn. Thus, Spn can target CaMKII to F-actin as well as target PP1 to CaMKII (Baucum et al., 2012).

Regulator of G-protein signalling (RGS) proteins play a crucial role in the shutting off process of G-protein-mediated responses (Ishii and Kurachi, 2003). Spn binds to different members of the RGS family (Wang et al., 2005; Wang et al., 2007). For example, Spn binds to through the 391-545 amino acids of the scaffolding protein and the 6-9 amino acids of the N-terminus of RGS8 (Fujii et al., 2008).

Guanine nucleotide exchange factors (GEF) activate small G protein through the exchange of bound GDP for GTP. Several GEF were shown to interact with Spn. For example, Spn, through its carboxy-terminus containing the PDZ and coiled-coil domains interacts with kalirin-7, the neuronal GEF for Rac1 (Penzes et al., 2001).

Spn interacts with some receptors that belong to the superfamily of GPCRs, mainly in the CNS. Using the 3i loop of the D2R, Spn has been identified as a protein that specifically associates with the receptor in rat hippocampal (Smith et al., 1999). The 3i loops of α2A-AR, α2B-AR, and α2C-AR subtypes interact also with Spn (Richman et al., 2001). More recently, it has been shown that the α1B-AR interacts with Spn in vitro (Wang et al., 2005). In the cerebellum, Spn can bind to the M1-m-AChR using the receptor binding domain of the scaffolding protein (Fujii et al., 2008). Spn can also interact with the M2- and M3-m-AchRs but the binding ability to the M3-m-AChR seems to be weaker than those to the M1- and M2-m-AChR (Wang et al., 2007; Kurogi et al., 2009). Moreover, Spn binds to the 3i loop of CCKA and CCKB receptors (Wang et al., 2007). The receptor binding domain of Spn also associates with the 3i loop and a conserved region of the C-terminal tails of δ- and μ-OR (Fourla et al., 2012). Spn also interacts with the ionotropic NMDA and AMPA-type glutamate receptors. PDZ domain directly binds to GluR2-, GluR3- (AMPA receptor) and NR1C2'-, NR2A/B- and NR2C/D- (NMDA receptor) derived peptides (Kelker et al., 2007).

TRPC ion channels are Ca2+ /cation selective channels that are highly expressed in the central nervous system. Spn was identified with other dendritic spines proteins as a protein partner of TRPC5 and TRPC6 channels (Goel et al., 2005). In cardiomyocytes, Spn targets PP1 to RYR2 via binding to a leucine zipper (LZ) motif of RYR2 and a LZ motif on Spn (amino acids 300-634) causing dephosphorylation and modulation of the channel activity (Marx et al., 2001).

TGN38 is an integral membrane protein that constitutively cycles between the trans-Golgi network (TGN) and plasma membrane via endosomal intermediates. TGN38 directly interacts with the coiled-coil region of Spn, preferentially with the dimerized proteins (Stephens and Banting, 1999). Spn has been shown to interact with the nuclear protein ARF in mammalian cells. The amino acids sequence 605-726, of the coiled-coil region of Spn, seems to be involved and an intact ARF N-terminal region (amino acids 1-65) is necessary for this interaction (Vivo et al., 2001).

4- Spinophilin as a tumour suppressor

The Spn gene locus is located on chromosome 17 at position 17q21.33, a cytogenetic area frequently associated with microsatellite instability and loss of heterozygosity (LOH) observed in different human tumours. This region contains a relatively high density of known (such as BRCA1), putative as well as several yet-unidentified candidate tumour suppressor genes located distal to BRCA1 locus. Thus, several studies in breast and ovarian carcinomas have suggested the presence of an unknown tumour suppressor gene in the area that includes the Spn locus. However, despite these preliminary genetic correlations, no in-depth analysis of the role of Spn as a tumour suppressor has been made.

The Amancio Carnero laboratory from the Instituto de Biomedicine de Sevilla, in Spain, have addressed this possibility in vitro and in vivo, in three articles published in 2011. In the first study, immunohistochemical analysis of 35 human lung tumours at different stages and of different histopathological grades showed that Spn protein is absent in 20% and reduced in another 37% of tumours, compared to normal lung tissue (Molina-Pinelo et al., 2011). The loss of Spn expression correlated with a less differentiated phenotype, higher grade and poor prognosis. Lower or null levels of Spn also correlated with nuclear accumulation of p53, and so to mutated p53 or loss of its wild-type activity. Moreover, loss of Spn increased the tumourigenic properties of p53 deleted- or p53 mutated-lung tumour cells. The data of this study showed that Spn down-regulation in lung tumours contributes to carcinogenesis in the absence of p53. There are several mechanisms that might contribute to Spn down-regulation in tumours, including miRNAs overexpression. miRNA106*, targeting Spn, are overexpressed in a small subset of patients with decreased Spn levels. Overexpression of miRNA106* significantly increased the tumorigenic properties of lung tumour cells. The results suggested that miRNA106* overexpression found in a subset of lung tumours might contribute to tumorigenesis through Spn down-regulation in the absence of p53. In a second study, tumour suppression by Spn was explored in in vivo model using genetically modified mice (Ferrer et al., 2011b). Spn-null (-/-) mice displayed decreased survival, increased the number of premalignant lesions in tissues such as the mammary ducts and early appearance of spontaneous tumours, such as lymphoma, when compared to WT littermates. In another series of experiments, the presence of mutant p53 activity (p53R172H) in the mammary glands was evaluated on a Spn heterozygous (+/-) or homozygous (-/-) background in mice. An increased number of premalignant lesions and of mammary carcinomas were observed in Spn heterozygous (+/-) or homozygous (-/-) mice when compared to WT littermates. The results confirmed the functional relationship between Spn and p53 in tumorigenicity and showed that Spn loss contributes to tumour progression rather than the tumour initiation. In a third study using mouse embryonic fibroblasts (MEFs), it was suggested that Spn acts as a tumour suppressor by the regulation of the stability of PP1cα, thereby regulating its activity on pRb (the phosphorylated form of the Retinoblastoma protein). This function of PP1cα has been associated with the growth arrest response; the hypophosphorylated form of Rb protein being the most abundant when cells are delayed in their growth (Ceulemans and Bollen, 2004). The ectopic overexpression of Spn in immortalized MEF greatly reduced tumour cell growth. Moreover, the absence of Spn (Spn(-/-) MEF) down-regulated PP1α activity resulting in a high level of pRb (Ferrer et al., 2011a). High level of proproliferative phosphorylated Rb leads to e2F activation, a compensatory ARF transcription, and consequently p53 activation. As they regulate the cell cycle, p53 and ARF are both tumour suppressors, which are themselves regulated by MDM2 (Mouse double minute 2) protein shuttle between the nucleus and cytoplasm (Kamijo et al., 1998; Pomerantz et al., 1998). Moreover, Sherr et al. (2005) suggested for the first time a p53-independent pathway via the ARF sumoylation. Ha et al. (2007) described ARF as a melanoma tumour suppressor by inducing p53-independent senescence. Moreover, Du et al. (2011) demonstrated the functional roles of ERK and p21 for ARF in p53-independent tumour suppression. Furthermore, in a p53-independent pathway, the over-expression of wild-type c-myc obviously up-regulates the expression of p14 (ARF) (Liu et al., 2012). Some members of the family of e2F transcription factors are also involved in cell cycle regulation; in particular E2F1 which expressions increase induces augmentation of ARF which can bind MDM2 and stabilize p53. In p53 (- / -) MEF, reduced levels of Spn enhanced tumorigenic potential of the cells. Indeed, inhibition of e2F by Rb being lifted, this results in cell proliferation no longer controlled by p53. Moreover, the absence of Spn contributes to genetic alterations during MEF immortalization, particularly p53 mutations. These results extend the observations made by the authors using a Spn-null mice model (Ferrer et al., 2011b).

In summary, the results suggested that Spn is a new tumour suppressor acting via the regulation of pRb and which function is revealed in the absence of a functional p53 (Sarrouilhe and Ladeveze, 2012). This is, therefore, suggestive of partially redundant functions in their tumour suppression properties (Santamaría and Malumbres, 2011). The results also suggest that the specific outcome can be context-dependent. Spn loss may be beneficial by potentiating p53 in response to acute stress, and in contrast it can be deleterious under sustained mitogenic stress (Palmero, 2011). This feature is reminiscent of NIAM (Nucleolar Interaction of ARF and MDM2 protein) which acts through the same partners p53 and ARF (Tompkins et al., 2007).

Another Spn-interacting molecule is DCX, an actin-binding and microtubule-binding protein that seems to be a tumour suppressor of glioma. When DCX is ectopically expressed into the DCX-deficient U87 glioma cells, there is a marked suppression of the transformed phenotype. The cells manifest a reduced rate of growth in vitro and are arrested in the G2 phase of the cell cycle. Moreover, DCX-transfected U87 glioma cells do not generate tumours in immunocompromised nude rats. In DCX-transfected U87 cells, phosphorylated DCX binds specifically to Spn and this interaction inhibits proliferation and anchorage-independent growth in glioma cells. In contrast, DCX-mediated growth repression is lost in glioma cells treated with siRNA to Spn and in HEK 293 (human embryonic kidney) Spn null cell line (Santra et al., 2006). DCX, Spn and PP1c were found in the same protein complex from mouse brain extracts (Shmueli et al., 2006). DCX-mediated growth arrest in glioma cells may be through inactivation of PP1 activity by Spn/DCX interaction in the cytosol. Inhibition of PP1 activity is involved in two mechanistic links of reduction of glioma tumour-associated progressions: firstly, catastrophe in mitotic microtubule spindle that blocks mitosis; secondly, depolymerization of actin that inhibits glioma cell invasion (Santra et al., 2009). Moreover, double transfection with DCX and Spn reduced self-renewal in brain tumour stem cells via incomplete cell cycle endomitosis (Santra et al., 2011).

But, is there relevance for Spn as a prognostic marker in patients with cancer? Spn is absent in 20% and reduced in another 37% of human lung tumors (Molina-Pinelo et al., 2011). A further analysis of Spn in human tumours shows that Spn mRNA is lost in a percentage of renal carcinomas and lung adenocarcinomas. A clear down-regulation of Spn was found in tumoral samples of the CNS (oligodendrogliomas, anaplastic astrocytomas, glioblastomas) when compared to normal nervous samples. Furthermore, lower levels of Spn mRNA correlate with higher grade of ovarian carcinoma and chronic myelogenous leukemia (Carnero, 2012). Two articles published in spring 2013 associated Spn loss with poor patient prognosis in patients with carcinoma (Sarrouilhe, 2014). The 17q chromosomal region is commonly impaired in hepatocellular carcinoma (Furge et al., 2005). In the first study, complete loss of Spn immunoreactivity was found in 42.3% hepatocellular carcinoma and reduced levels were found in additional 35.6% cases. Quantitative RT-PCR analysis confirmed in 70% cases a significant reduced Spn mRNA expression in tumour tissue compared with the corresponding non-neoplastic tissue. miRNA106*, targeting Spn in lung tumours, could not be detected in any of the hepatocellular carcinoma samples. Moreover, no correlations could be found for the number of Spn-positive tumour cells and p53 or ARF staining. These results suggested a p53-independent tumorigenic role of Spn in hepatocellular carcinoma. Disease recurrence was diagnosed after the 10-year follow-up in 85.2% cases with Spn low expression and 60.9% with Spn high expression. Death occurred in 76.5% cases with Spn low expression and in 56.5% cases with Spn high expression. Overall, low Spn expression is a factor for poor prognosis in hepatocellular carcinoma. In vitro experiments (human hepatoma cell line HepG2) and in vivo observations (Ki67-positive tumour cells) showed that reduced Spn expression significantly correlated with a higher proliferation of liver cancer cells (Aigelsreiter et al., 2013).

In the second study, the role of Spn was explored in colorectal carcinoma, in which a number of chromosomal regions are altered (Fearon, 2011). Among them, the 17q21 is lost in a high percentage of this carcinoma (Garcia-Patiño et al., 1998). Quantitative RT-PCR analysis showed that approximately 25% of colorectal carcinoma tumours had a greater than 50% decrease in Spn mRNA levels compared with normal colonic tissue. A tissue array of human colorectal carcinomas was generated to confirm this result by exploring the presence of Spn protein. 70% of colorectal carcinomas displayed high Spn levels (similar to the values observed in normal tissue), 20% showed intermediate levels and 10% showed no expression of Spn. Moreover, Spn down-regulation correlated with a more aggressive histologic phenotype (higher Ki67-positive tumour cells) and was associated with faster relapse and poorer survival in patients with advanced stages of colorectal carcinoma. The data also suggested that Spn loss induced a chemoresistance in patients with advanced stages of colorectal carcinoma that had received adjuvant fluoropyrimidine chemotherapy following surgical resection. Therefore, the identification of the levels of Spn in advanced stages of colorectal biopsies has prognostic and predictive value and might contribute to select patients who could or could not benefit from current chemotherapy. In vitro and in vivo experiments showed no functional relationship between Spn levels and the presence or absence of mutated p53 in colon cancer. The authors proposed that this correlation is dependent on the molecular context of the tumour cell (Estevez-Garcia et al., 2013).

5- Discussion and perspectives

Figure 3. Cellular cycle regulation by spinophilin. A. In normal cells, the presence of nuclear p53 and Spn proteins regulates cell cycle. The binding of PP1ca to Spn allows dephosphorylation of pRb, which inhibits E2F1 and thus the proliferation. Furthermore both tumour suppressors (p53 and ARF) regulate the cell cycle. The nucleolar ARF is also a partner of Spn, and regulates the cell cycle via Mdm2 and E2F1. B. In the case of colorectal carcinomas, Spn play a role in regulation of cell cycle via a p53/ARF independent pathway. One hypothesis suggested by the team of Amancio Carnero is that the Ras/Raf pathway could be implicated (Estevez-Garcia et al., 2013). This cytoplasmic pathway could be regulated by cytoplasmic Spn. K-Ras: GTPase, oncogene; B-Raf: serine/threonine protein kinase, proto-oncogene; Mek: tyrosine/threonine kinase (Mapk kinase); Mapk: mitogen-activated protein kinase.

We are still only at the early stage in unravelling the function of Spn in cell cycle regulation. Overall, the different studies on the tumour suppressor function of Spn show two pathways of cell cycle regulation by Spn. The first model is a pathway dependent of p53 and ARF. This pathway was previously described in several articles where Spn interacts with different partners localized in the nucleus (Figure 3A). The second is a pathway independent of both molecules. As Spn is ubiquitously expressed in the cell, the first model highlights the nuclear localization of Spn and its interaction with other nuclear proteins. The second model, more hypothetical, underlines the possibility that Spn could interact with cytoplasmic partners. The studies made on colorectal carcinomas show that Spn could play a role in a pathway independent of p53/ARF. One hypothesis is that the Ras/Raf pathway and more precisely K-Ras/B-Raf is implicated. This pathway, via Mek (tyrosine/threonine kinase) and Mapk (mitogen activated protein kinase) induces transcription factors and proliferation survical (Figure 3B).

Further studies are needed to elucidate the underlying mechanisms linking Spn to carcinomas and expand the prognostic and predictive value of the Spn expression level to other types of cancer.

Bibliography

Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1 alpha gene in rat hepatocellular carcinomas.
Sasaki K, Shima H, Kitagawa Y, Irino S, Sugimura T, Nagao M.
Jpn J Cancer Res. 1990 Dec;81(12):1272-80.
PMID 2177460
 
Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines.
Allen PB, Ouimet CC, Greengard P.
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9956-61.
PMID 9275233
 
Neurabin: a novel neural tissue-specific actin filament-binding protein involved in neurite formation.
Nakanishi H, Obaishi H, Satoh A, Wada M, Mandai K, Satoh K, Nishioka H, Matsuura Y, Mizoguchi A, Takai Y.
J Cell Biol. 1997 Nov 17;139(4):951-61.
PMID 9362513
 
Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton.
Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM, Snyder SH.
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8351-6.
PMID 9653190
 
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
Garcia-Patino E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, Cubedo R, Espana P, Ramon y Cajal S, Bonilla F.
Cancer Genet Cytogenet. 1998 Jul 15;104(2):119-23.
PMID 9666805
 
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ.
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7.
PMID 9653180
 
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA.
Cell. 1998 Mar 20;92(6):713-23.
PMID 9529248
 
Neurabin-II/spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites.
Satoh A, Nakanishi H, Obaishi H, Wada M, Takahashi K, Satoh K, Hirao K, Nishioka H, Hata Y, Mizoguchi A, Takai Y.
J Biol Chem. 1998 Feb 6;273(6):3470-5.
PMID 9452470
 
Brain actin-associated protein phosphatase 1 holoenzymes containing spinophilin, neurabin, and selected catalytic subunit isoforms.
MacMillan LB, Bass MA, Cheng N, Howard EF, Tamura M, Strack S, Wadzinski BE, Colbran RJ.
J Biol Chem. 1999 Dec 10;274(50):35845-54.
PMID 10585469
 
Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein.
Smith FD, Oxford GS, Milgram SL.
J Biol Chem. 1999 Jul 9;274(28):19894-900.
PMID 10391935
 
Direct interaction of the trans-Golgi network membrane protein, TGN38, with the F-actin binding protein, neurabin.
Stephens DJ, Banting G.
J Biol Chem. 1999 Oct 15;274(42):30080-6.
PMID 10514494
 
Spinophilin regulates the formation and function of dendritic spines.
Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, Zhuo M, Allen PB, Ouimet CC, Greengard P.
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9287-92.
PMID 10922077
 
Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers.
Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, Rosemblit N, Marks AR.
J Cell Biol. 2001 May 14;153(4):699-708.
PMID 11352932
 
The neuronal Rho-GEF Kalirin-7 interacts with PDZ domain-containing proteins and regulates dendritic morphogenesis.
Penzes P, Johnson RC, Sattler R, Zhang X, Huganir RL, Kambampati V, Mains RE, Eipper BA.
Neuron. 2001 Jan;29(1):229-42.
PMID 11182094
 
Agonist-regulated Interaction between alpha2-adrenergic receptors and spinophilin.
Richman JG, Brady AE, Wang Q, Hensel JL, Colbran RJ, Limbird LE.
J Biol Chem. 2001 May 4;276(18):15003-8. Epub 2001 Jan 11.
PMID 11154706
 
The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein.
Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, Saviozzi S, La Mantia G.
J Biol Chem. 2001 Apr 27;276(17):14161-9. Epub 2001 Jan 30.
PMID 11278317
 
Protein phosphatase 1--targeted in many directions.
Cohen PT.
J Cell Sci. 2002 Jan 15;115(Pt 2):241-56. (REVIEW)
PMID 11839776
 
Targeting protein phosphatase 1 (PP1) to the actin cytoskeleton: the neurabin I/PP1 complex regulates cell morphology.
Oliver CJ, Terry-Lorenzo RT, Elliott E, Bloomer WA, Li S, Brautigan DL, Colbran RJ, Shenolikar S.
Mol Cell Biol. 2002 Jul;22(13):4690-701.
PMID 12052877
 
The neuronal actin-binding proteins, neurabin I and neurabin II, recruit specific isoforms of protein phosphatase-1 catalytic subunits.
Terry-Lorenzo RT, Carmody LC, Voltz JW, Connor JH, Li S, Smith FD, Milgram SL, Colbran RJ, Shenolikar S.
J Biol Chem. 2002 Aug 2;277(31):27716-24. Epub 2002 May 16.
PMID 12016225
 
Analysis of specific interactions of native protein phosphatase 1 isoforms with targeting subunits.
Colbran RJ, Carmody LC, Bauman PA, Wadzinski BE, Bass MA.
Methods Enzymol. 2003;366:156-75.
PMID 14674248
 
Phosphorylation of spinophilin modulates its interaction with actin filaments.
Hsieh-Wilson LC, Benfenati F, Snyder GL, Allen PB, Nairn AC, Greengard P.
J Biol Chem. 2003 Jan 10;278(2):1186-94. Epub 2002 Nov 1.
PMID 12417592
 
Physiological actions of regulators of G-protein signaling (RGS) proteins.
Ishii M, Kurachi Y.
Life Sci. 2003 Dec 5;74(2-3):163-71. (REVIEW)
PMID 14607243
 
Identification of neurabin II as a novel doublecortin interacting protein.
Tsukada M, Prokscha A, Oldekamp J, Eichele G.
Mech Dev. 2003 Sep;120(9):1033-43.
PMID 14550532
 
A protein phosphatase-1gamma1 isoform selectivity determinant in dendritic spine-associated neurabin.
Carmody LC, Bauman PA, Bass MA, Mavila N, DePaoli-Roach AA, Colbran RJ.
J Biol Chem. 2004 May 21;279(21):21714-23. Epub 2004 Mar 11.
PMID 15016827
 
Functional diversity of protein phosphatase-1, a cellular economizer and reset button.
Ceulemans H, Bollen M.
Physiol Rev. 2004 Jan;84(1):1-39. (REVIEW)
PMID 14715909
 
Spinophilin is phosphorylated by Ca2+/calmodulin-dependent protein kinase II resulting in regulation of its binding to F-actin.
Grossman SD, Futter M, Snyder GL, Allen PB, Nairn AC, Greengard P, Hsieh-Wilson LC.
J Neurochem. 2004 Jul;90(2):317-24.
PMID 15228588
 
Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines.
Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ.
Am J Psychiatry. 2004 Oct;161(10):1848-55.
PMID 15465982
 
Cellular and subcellular distribution of spinophilin, a PP1 regulatory protein that bundles F-actin in dendritic spines.
Ouimet CC, Katona I, Allen P, Freund TF, Greengard P.
J Comp Neurol. 2004 Nov 22;479(4):374-88.
PMID 15514983
 
Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
Brown AM, Deutch AY, Colbran RJ.
Eur J Neurosci. 2005 Jul;22(1):247-56.
PMID 16029214
 
Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma.
Furge KA, Dykema KJ, Ho C, Chen X.
BMC Genomics. 2005 May 9;6:67.
PMID 15882461
 
Phosphorylation of spinophilin by ERK and cyclin-dependent PK 5 (Cdk5).
Futter M, Uematsu K, Bullock SA, Kim Y, Hemmings HC Jr, Nishi A, Greengard P, Nairn AC.
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3489-94. Epub 2005 Feb 22.
PMID 15728359
 
Proteomic analysis of TRPC5- and TRPC6-binding partners reveals interaction with the plasmalemmal Na(+)/K(+)-ATPase.
Goel M, Sinkins W, Keightley A, Kinter M, Schilling WP.
Pflugers Arch. 2005 Oct;451(1):87-98. Epub 2005 Jul 16.
PMID 16025302
 
p53-Dependent and -independent functions of the Arf tumor suppressor.
Sherr CJ, Bertwistle D, DEN Besten W, Kuo ML, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF.
Cold Spring Harb Symp Quant Biol. 2005;70:129-37. (REVIEW)
PMID 16869746
 
Doublecortin association with actin filaments is regulated by neurabin II.
Tsukada M, Prokscha A, Ungewickell E, Eichele G.
J Biol Chem. 2005 Mar 25;280(12):11361-8. Epub 2005 Jan 4.
PMID 15632197
 
Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors.
Wang X, Zeng W, Soyombo AA, Tang W, Ross EM, Barnes AP, Milgram SL, Penninger JM, Allen PB, Greengard P, Muallem S.
Nat Cell Biol. 2005 Apr;7(4):405-11. Epub 2005 Mar 27.
PMID 15793568
 
Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity.
Allen PB, Zachariou V, Svenningsson P, Lepore AC, Centonze D, Costa C, Rossi S, Bender G, Chen G, Feng J, Snyder GL, Bernardi G, Nestler EJ, Yan Z, Calabresi P, Greengard P.
Neuroscience. 2006 Jul 7;140(3):897-911.
PMID 16600521
 
Ectopic doublecortin gene expression suppresses the malignant phenotype in glioblastoma cells.
Santra M, Zhang X, Santra S, Jiang F, Chopp M.
Cancer Res. 2006 Dec 15;66(24):11726-35.
PMID 17178868
 
Spinophilin: from partners to functions.
Sarrouilhe D, di Tommaso A, Metaye T, Ladeveze V.
Biochimie. 2006 Sep;88(9):1099-113. Epub 2006 May 17. (REVIEW)
PMID 16737766
 
Site-specific dephosphorylation of doublecortin (DCX) by protein phosphatase 1 (PP1).
Shmueli A, Gdalyahu A, Sapoznik S, Sapir T, Tsukada M, Reiner O.
Mol Cell Neurosci. 2006 May-Jun;32(1-2):15-26. Epub 2006 Mar 10.
PMID 16530423
 
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.
Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, Merlino G.
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968-73. Epub 2007 Jun 19.
PMID 17576930
 
Structural basis for spinophilin-neurabin receptor interaction.
Kelker MS, Dancheck B, Ju T, Kessler RP, Hudak J, Nairn AC, Peti W.
Biochemistry. 2007 Mar 6;46(9):2333-44. Epub 2007 Feb 6.
PMID 17279777
 
A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.
Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE.
J Biol Chem. 2007 Jan 12;282(2):1322-33. Epub 2006 Nov 16.
PMID 17110379
 
Spinophilin/neurabin reciprocally regulate signaling intensity by G protein-coupled receptors.
Wang X, Zeng W, Kim MS, Allen PB, Greengard P, Muallem S.
EMBO J. 2007 Jun 6;26(11):2768-76. Epub 2007 Apr 26.
PMID 17464283
 
Selective targeting of the gamma1 isoform of protein phosphatase 1 to F-actin in intact cells requires multiple domains in spinophilin and neurabin.
Carmody LC, Baucum AJ 2nd, Bass MA, Colbran RJ.
FASEB J. 2008 Jun;22(6):1660-71. doi: 10.1096/fj.07-092841. Epub 2008 Jan 23.
PMID 18216290
 
Multiple actions of spinophilin regulate mu opioid receptor function.
Charlton JJ, Allen PB, Psifogeorgou K, Chakravarty S, Gomes I, Neve RL, Devi LA, Greengard P, Nestler EJ, Zachariou V.
Neuron. 2008 Apr 24;58(2):238-47. doi: 10.1016/j.neuron.2008.02.006.
PMID 18439408
 
Spinophilin inhibits the binding of RGS8 to M1-mAChR but enhances the regulatory function of RGS8.
Fujii S, Yamazoe G, Itoh M, Kubo Y, Saitoh O.
Biochem Biophys Res Commun. 2008 Dec 5;377(1):200-4. doi: 10.1016/j.bbrc.2008.09.096. Epub 2008 Oct 1.
PMID 18834863
 
Structure-function analysis of the filamentous actin binding domain of the neuronal scaffolding protein spinophilin.
Schuler H, Peti W.
FEBS J. 2008 Jan;275(1):59-68. Epub 2007 Nov 20.
PMID 18028445
 
Neurabin contributes to hippocampal long-term potentiation and contextual fear memory.
Wu LJ, Ren M, Wang H, Kim SS, Cao X, Zhuo M.
PLoS One. 2008 Jan 9;3(1):e1407. doi: 10.1371/journal.pone.0001407.
PMID 18183288
 
Effects of spinophilin on the function of RGS8 regulating signals from M2 and M3-mAChRs.
Kurogi M, Nagatomo K, Kubo Y, Saitoh O.
Neuroreport. 2009 Aug 26;20(13):1134-9. doi: 10.1097/WNR.0b013e32832fd93e.
PMID 19609226
 
Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion.
Santra M, Santra S, Roberts C, Zhang RL, Chopp M.
J Neurochem. 2009 Jan;108(1):231-45. doi: 10.1111/j.1471-4159.2008.05758.x.
PMID 19094064
 
Spinophilin directs protein phosphatase 1 specificity by blocking substrate binding sites.
Ragusa MJ, Dancheck B, Critton DA, Nairn AC, Page R, Peti W.
Nat Struct Mol Biol. 2010 Apr;17(4):459-64. doi: 10.1038/nsmb.1786. Epub 2010 Mar 21.
PMID 20305656
 
ARF triggers cell G1 arrest by a P53 independent ERK pathway.
Du H, Yao W, Fang M, Wu D.
Mol Cell Biochem. 2011 Nov;357(1-2):415-22. doi: 10.1007/s11010-011-0912-4. Epub 2011 Jun 10.
PMID 21660463
 
Molecular genetics of colorectal cancer.
Fearon ER.
Annu Rev Pathol. 2011;6:479-507. doi: 10.1146/annurev-pathol-011110-130235. (REVIEW)
PMID 21090969
 
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.
Ferrer I, Blanco-Aparicio C, Peregrina S, Canamero M, Fominaya J, Cecilia Y, Lleonart M, Hernandez-Losa J, Ramon y Cajal S, Carnero A.
Cell Cycle. 2011a Aug 15;10(16):2751-62. Epub 2011 Aug 15.
PMID 21772120
 
Spinophilin loss contributes to tumorigenesis in vivo.
Ferrer I, Peregrino S, Canamero M, Cecilia Y, Blanco-Aparicio C, Carnero A.
Cell Cycle. 2011b Jun 15;10(12):1948-55. Epub 2011 Jun 15.
PMID 21670604
 
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.
Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, Suarez R, Verge M, Marin JJ, Hernandez-Losa J, Ramon y Cajal S, Paz-Ares L, Carnero A.
J Pathol. 2011 Sep;225(1):73-82. doi: 10.1002/path.2905. Epub 2011 May 19.
PMID 21598252
 
New role for Spinophilin in tumor suppression.
Palmero I.
Cell Cycle. 2011 Oct 15;10(20):3427. doi: 10.4161/cc.10.20.17527. Epub 2011 Oct 15.
PMID 22024930
 
Flexibility in the PP1:spinophilin holoenzyme.
Ragusa MJ, Allaire M, Nairn AC, Page R, Peti W.
FEBS Lett. 2011 Jan 3;585(1):36-40. doi: 10.1016/j.febslet.2010.11.022. Epub 2010 Nov 19.
PMID 21094159
 
Tumor suppression by Spinophilin.
Santamaria D, Malumbres M.
Cell Cycle. 2011 Sep 1;10(17):2831-2. Epub 2011 Sep 1.
PMID 21869595
 
Effect of doublecortin on self-renewal and differentiation in brain tumor stem cells.
Santra M, Santra S, Buller B, Santra K, Nallani A, Chopp M.
Cancer Sci. 2011 Jul;102(7):1350-7. doi: 10.1111/j.1349-7006.2011.01952.x. Epub 2011 May 10.
PMID 21477071
 
Age-dependent targeting of protein phosphatase 1 to Ca2+/calmodulin-dependent protein kinase II by spinophilin in mouse striatum.
Baucum AJ 2nd, Strack S, Colbran RJ.
PLoS One. 2012;7(2):e31554. doi: 10.1371/journal.pone.0031554. Epub 2012 Feb 13.
PMID 22348105
 
Spinophilin: a new tumor suppressor at 17q21.
Carnero A.
Curr Mol Med. 2012 Jun;12(5):528-35. (REVIEW)
PMID 22515982
 
Selective interactions of spinophilin with the C-terminal domains of the ?- and ?-opioid receptors and G proteins differentially modulate opioid receptor signaling.
Fourla DD, Papakonstantinou MP, Vrana SM, Georgoussi Z.
Cell Signal. 2012 Dec;24(12):2315-28. doi: 10.1016/j.cellsig.2012.08.002. Epub 2012 Aug 18.
PMID 22922354
 
[Regulation of p14(ARF) expression and induction of cell apoptosis with c-myc in a p53-independent pathway].
Liu XJ, Li FN, Jiang DD, Wang XG, Liu XP, Zhang DL, Meng CH.
Zhonghua Yi Xue Za Zhi. 2012 Aug 14;92(30):2140-3.
PMID 23158280
 
A newly identified complex of spinophilin and the tyrosine phosphatase, SHP-1, modulates platelet activation by regulating G protein-dependent signaling.
Ma P, Cierniewska A, Signarvic R, Cieslak M, Kong H, Sinnamon AJ, Neubig RR, Newman DK, Stalker TJ, Brass LF.
Blood. 2012 Feb 23;119(8):1935-45. doi: 10.1182/blood-2011-10-387910. Epub 2011 Dec 30.
PMID 22210881
 
[When the curtain goes up on spinophilin's tumor suppressor function].
Sarrouilhe D, Ladeveze V.
Med Sci (Paris). 2012 Jan;28(1):26-8. doi: 10.1051/medsci/2012281009. Epub 2012 Jan 27.
PMID 22289823
 
Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma.
Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, Kiesslich T, Stojakovic T, Samonigg H, Kornprat P, Lackner C, Haybaeck J, Pichler M.
Br J Cancer. 2013 May 14;108(9):1830-7. doi: 10.1038/bjc.2013.165. Epub 2013 Apr 16.
PMID 23591196
 
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.
Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Munoz-Galvan S, Salinas A, Gomez-Izquierdo L, Lucena-Cacace A, Felipe-Abrio B, Paz-Ares L, Garcia-Carbonero R, Carnero A.
Clin Cancer Res. 2013 Jul 15;19(14):3925-35. doi: 10.1158/1078-0432.CCR-13-0057. Epub 2013 May 31.
PMID 23729363
 
[The loss of expression of spinophilin is associated with a bad prognosis in hepatocellular and colorectal carcinomas].
Sarrouilhe D.
Bull Cancer. 2014 Jan 1;101(1):5-6.
PMID 24649497
 
Written2014-02Denis Sarrouilhe, Véronique Ladeveze
de Physiologie Humaine, Faculte de Medecine et Pharmacie, Universite de Poitiers, 6 rue de la Miletrie, Bat D1, TSA 51115, 86073 Poitiers, Cedex 9, France (DS); Laboratoire de Genetique Moleculaire de Maladies Rares, Universite de Poitiers, UFR SFA, Pole Biologie Sante, Bat B36, TSA 51106, 86073 Poitiers, Cedex 9, France (VL)

Citation

This paper should be referenced as such :
D Sarrouilhe, V Ladeveze
The tumour suppressor function of the scaffolding protein spinophilin
Atlas Genet Cytogenet Oncol Haematol. 2014;18(9):691-700.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Deep/SpinophilinID20133.htm

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:22:26 CEST 2017


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.